Boehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.
Formulary Watch
Latest News
All News
Advertisement
FDA is warning about ketoacidosis and urinary tract infections associated with the relatively new class of type 2 diabetes medicines called sodium-glucose cotransporter-2 (SGLT2) inhibitors such as Invokana and Jardiance.
FDA has approved recombinant von Willebrand factor (Vonvendi, Baxalta) for use in adults who have von Willebrand disease.
FDA has approved methylphenidate hydrochloride (QuilliChew ER, Pfizer) extended-release chewable tablets for the treatment of ADHD in children.
Genetically engineered chickens were needed to produce Kanuma (sebelipase alfa), newly approved by FDA to treat lysosomal acid lipase deficiency (LAL-D), a genetic and progressive ultra-rare metabolic disease in which patients suffer multi-organ damage and premature death.
Pharmacists in California and Oregon will soon be able to prescribe birth control.
The Pulmonary Fibrosis Foundation and Boehringer Ingelheim’s new five-year partnership, aims to raise awareness of pulmonary fibrosis, provide disease education and advance care and funding research for the PF community
A new US Congressional report about the price of hepatitis C drug Sovaldi, along with a new class action lawsuit against Blue Cross Blue Shield involving Harvoni coverage, are the latest in a series of controversies surrounding the 2 drugs.
FDA has approved elotuzumab (Empliciti, Bristol-Myers Squibb and AbbVie) for the treatment of multiple myeloma.
A study published in the October 26th issue of the JAMA Internal Medicine journal shows that physicians don't typically reduce older patients' diabetic medications, even when the patients have low blood sugar levels.
Advertisement
A new joint program with the Mount Sinai Health System and Livongo Health, a consumer digital health company, is expected to help diabetics manage their disease better.
In its latest round of cancer drug approvals, the FDA last week approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC).
FDA approved nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic renal cell carcinoma.
FDA this week approved a new indication for BioThrax to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease.
In FDA’s latest approval of a new medication to treat multiple myeloma, the agency approved Ninlaro capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Most idiopathic pulmonary fibrosis patients have considerably impaired lung function and gastroesophageal reflux disease is the most common co-morbidity, according to initial results from the IPF-PRO Registry.
Manufactured by Adapt Pharma, Narcan is the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Up until now, naloxone has only been available in an injectable form.
FDA has approved cobimetinib (Cotellic, Genentech) to be used in combination with vemurafenib (Zelboraf) for the treatment of advanced melanoma.
The FDA accelerated approval for Darzalex injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or who are double-refractory to a PI and an immunomodulatory agent.
FDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.
FDA approved Yondelis (trabectedin), by Janssen Biotech for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.
FDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.
Sarilumab, an investigational, human antibody against the IL-6 receptor, is highly effective in the difficult-to-treat TNF-IR population in rheumatoid arthritis (RA), according to data presented during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.
A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.
The Food and Drug Administration last week approved Genvoya, marketed by Gilead Sciences, to treat HIV-1 infection.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Patient-facing EHR tool improves lung cancer screening identification
2
How California is rewriting the PBM playbook
3
DOD-funded study explores metformin as potential therapy for IPF
4
Adding NB-UVB phototherapy to ruxolitinib cream speeds vitiligo repigmentation process
5